Background-Atrial fibrillation (AF) promotes atrial remodeling and can develop secondary to heart failure or mitral valve disease. Cardiac endothelin-1 (ET-1) expression responds to wall stress and can promote myocyte hypertrophy and interstitial fibrosis. We tested the hypothesis that atrial ET-1 is elevated in AF and is associated with AF persistence. Methods and Results-Left atrial appendage tissue was studied from coronary artery bypass graft, valve repair, and/or Maze procedure in patients in sinus rhythm with no history of AF (SR, nϭ21), with history of AF but in SR at surgery (AF/SR, nϭ23), and in AF at surgery (AF/AF, nϭ32). The correlation of LA size with atrial protein and mRNA expression of ET-1 and ET-1 receptors (ETAR and ETBR)was evaluated. LA appendage ET-1 content was higher in AF/AF than in SR, but receptor levels were similar. Immunostaining revealed that ET-1 and its receptors were present both in atrial myocytes and in fibroblasts. ET-1 content was positively correlated with LA size, heart failure, AF persistence, and severity of mitral regurgitation. Multivariate analysis confirmed associations of ET-1 with AF, hypertension, and LA size. LA size was associated with ET-1 and MR severity. ET-1 mRNA levels were correlated with genes involved in cardiac dilatation, hypertrophy, and fibrosis. Conclusions-Elevated atrial ET-1 content is associated with increased LA size, AF rhythm, hypertension, and heart failure. ET-1 is associated with atrial dilatation, fibrosis, and hypertrophy and probably contributes to AF persistence.
Patient Selection
Left atrial appendage (LAA) specimens were obtained from patients referred to the Cleveland Clinic for cardiac surgical procedures in which the LAA was excised. Most patients had underlying structural heart disease. Clinical, laboratory, and demographic data were obtained by query of the Cardiovascular Information Registry, a comprehensive surgical data base. All patients provided informed consent; the protocol was approved by the Cleveland Clinic Institutional Review Board.
Patient samples were categorized into 3 groups, based on arrhythmia history. Control patients were in sinus rhythm (SR), with no history of AF or atrial flutter, but had other cardiac conditions requiring surgery (eg, coronary artery disease [CAD] , mitral valve disease [MVD] , or HF). AF patients included both those presenting to surgery in AF (AF/AF) and in SR (AF/SR), as documented on the last ECG before surgery. Patients included in the SR, AF/AF, and AF/SR groups were matched for age, sex, and history of HF, HTN, and MR.
Echocardiographic Analysis of LA Dimensions
Digitally archived echocardiographic recordings were sequentially reviewed and LA dimensions were assessed in 2-and 4-chamber views by a single experienced cardiologist (A.Z.). LA diameters and volumes were indexed to body surface area (iLAD, iLAV). 16 
Enzyme-Linked Immunoassay for Atrial ET-1
After transport from the operating room to the laboratory, separate sections of each LAA specimen were fixed in paraformaldehyde or stored at Ϫ80°C for confocal and biochemical studies. ET-1 content of atrial homogenates was evaluated using an enzyme-linked immunoassay (Biomedica BI-20052).
Western Analysis
Western blots were used to evaluate ETA and ETB receptor protein expression in LAA homogenates. Proteins were extracted, quantified, and probed with rabbit anti-ETAR or ETBR (1:200, Alomone Labs) as previously described. 8 
Microarray Analysis
Total RNA was isolated from each specimen (Trizol) and mRNA levels were assayed using the Illumina HT12 microarray platform.
Immunostaining and Confocal Microscopy
Immunostaining and confocal microscopy was used to evaluate the distribution of ET-1 and its receptors (ETAR and ETBR) in LAA tissues as previously described. 8
Statistical Analysis
Data are expressed as meansϮstandard error unless otherwise specified. Univariate and multivariate linear regression analyses were performed to evaluate the association of clinical and demographic variables with atrial ET-1 levels and LA size. Normally distributed variables are presented using bar plots and analyzed using ANOVA. Non-normally distributed variables are presented using box plots and analyzed using Mann-Whitney or Kruskal-Wallis tests. Spearman correlation was used to measure relation of ET-1 mRNA to variables that were not normally distributed. Univariate analyses were performed using GraphPad Prism 4; multivariate analyses were performed using JMP 7.
Because atrial ET-1 levels were not normally distributed, a square root transformation of ET-1 levels was used in the multivariate linear regression model. The square root transformation of atrial ET-1 effectively normalized the data set. Values of PϽ0.05 were considered statistically significant.
Results

Atrial ET-1 and ET-1 Receptor Studies
Patient Characteristics LAA tissues from 76 patients were selected for biochemical and immunohistochemical analysis of atrial ET-1 and ET-1 receptor expression. 
ET-1 and AF Status
LAA ET-1 protein levels were evaluated in atrial homogenates. ET-1 content was greater in AF/AF patients than in SR Figure  1A ). To further assess the relation of LAA ET-1 content to AF persistence, AF patients were subgrouped into 3 matched sets: permanent AF (Pm), persistent AF (Ps), and paroxysmal AF (Px), (see Supplement, Table 1 ). Paroxysmal AF was defined as AF with spontaneous termination within 7 days.
Persistent AF lasted more than 7 days and required cardioversion for restoration of SR. Permanent AF was defined as long-lasting AF in which cardioversion was either contraindicated or ineffective. 17 
Determinants of LA Size
Echocardiographic data available from 71 patients were used to assess the relationships between atrial rhythm, LA size, and LA ET-1 content. Atrial ET-1 content was positively correlated with LA size; patients with higher ET-1 levels had larger iLADs (Spearman rϭ0.61, Pϭ1.08ϫ10 Ϫ7 , Figure 2A ) and iLAVs ( Figure 2B , rϭ0.5, Pϭ1.2ϫ10 Ϫ4 ). This relationship was further evaluated among rhythm groups. Patients in AF at surgery (AF/AF) showed a stronger correlation of atrial ET-1 content with iLAD (rϭ0.78, Pϭ2.9ϫ10 Ϫ5 ) than the AF/SR group (rϭ0.62, Pϭ0.0002). Intriguingly, no correlation was observed between atrial ET-1 level and iLAD among SR patients (rϭ0.24, Pϭ0.39). Because the groups were matched for other cardiovascular conditions, these data suggest that atrial rhythm modulates the relationship between LA ET-1 content and LA size. Because reentrant electric activity depends on tissue mass, it is not surprising that AF persistence is also associated with iLAD ( Figure 2C ). Together, these data show that ET-1 is associated with the factors that underlie AF persistence.
Severity of MR was also strongly associated with increased iLAD (Pϭ3.8ϫ10
Ϫ5 , Kruskal-Wallis, Figure 2D ) and iLAV (Pϭ0.00016, Kruskal-Wallis). Multivariate analysis identified severity of MR and square root of atrial ET-1 as the strongest predictors of LA enlargement, as assessed by both iLAD (R 2 ϭ0.51, Pϭ4.67ϫ10 Ϫ10 , dfϭ66, Table 3 ) and iLAV (R 2 ϭ0.40, Pϭ5.95ϫ10 Ϫ6 , dfϭ62). Interestingly, female sex was positively correlated with iLAD (Table 3) ; however, the effect size was small. In our data set, neither AF status nor history of HTN were significant univariate predictors of iLAD and were not included in multivariate regression models for iLAD. LA enlargement predicts mortality for HF patients. HF was a univariate predictor of both iLAD and atrial ET-1 and a predictor of iLAD by stepwise analysis; however, presence of ET-1 in the model masked this relation. Although MR severity and atrial ET-1 are related, both were strong predictors of iLAD in our multivariate model (Table 3) .
Sources of Atrial ET-1
Although ET-1 is prominently produced by vascular endothelial and smooth muscle cells, 9 ET-1 has also been reported to be produced by cardiac myocytes 18 and fibroblasts. 19 Confocal microscopy ( Figure 3) confirmed that atrial ET-1 staining (red) is detectable in both cardiac myocytes and in fibroblasts (green). Consistent with our biochemical results, the intensity of ET-1 staining was associated with atrial rhythm. ET-1 staining was heterogeneously distributed.
ET-1 Receptor Distribution and Density in Human AF
ET-1 receptor activity modulates intracellular signaling pathways that affect contractility, excitability, and transcription. In a subset of 45 patients (9 SR, 14 AF/SR, and 21 AF/AF), Western blot analysis was used to assess ET-1 receptor density (ETAR and ETBR) relative to GAPDH. ETAR and ETBR density did not differ between study groups (Kruskal-Wallis test). This finding was confirmed by multivariate analysis, adjusting for possible confounders (eg, HF, HTN, MR, age, sex, LA size, and CAD) ( Figure 4A through 4D) . Receptor distribution was also evaluated using immunohistochemistry. Confocal imaging showed no differences in ETAR distribution among the groups (Online Supplement, Figure 1 ). ETAR (green) was abundantly expressed in cardiac myocytes (red) and in fibroblasts (purple), with no obvious differences in receptor localization between groups. ETAR expression in cardiac myocytes was most apparent in the cell membrane and intercalated disk regions, with less cytosolic staining and minimal localization in the nucleus (blue). In fibroblasts, ETAR was expressed in the cytosol and the nucleus (Online Supplement, Figure 1) .
In contrast to ETAR, distribution of ETBR (green) in cardiac myocytes was more cytosolic, and ETBR was more abundant in the nucleus. In fibroblasts, ETBR was expressed in the cytosol and the nucleus (Online Supplement, Figure 2 ).
LAA ET-1 content was weakly correlated with ETAR expression ( Figure 4E ) but not with ETBR expression, suggesting that ET-1 may modulate ETAR protein expression. Interestingly, ETAR protein expression was significantly correlated with ETBR protein expression ( Figure 4F ), suggesting that ET-1-independent mechanisms also modulate receptor expression.
Microarray Results
Microarrays facilitate simultaneous comparisons of mRNA levels for many different genes. Illumina HT-12 expression arrays were used to characterize mRNA expression profiles in LAA specimens from 205 patients, 66 of whom overlapped with those in Table 1 , above. Table 4 summarizes clinical and demographic characteristics of these patients.
Atrial ET-1 protein content and mRNA levels (EDN1) were correlated (Spearman rϭ0.32, Pϭ0.0108, Figure 5A ), suggesting that the ET-1 protein detected has an atrial origin. As reported in the subset of patients with LAA ET-1 measurements (Figure 2A ), EDN1 expression levels were also correlated, though more weakly, with iLAD (rϭ0.22, Pϭ0.01). Interestingly, Figure 5B and 5C show that mRNA expression of endothelin-converting enzyme (ECE2) was associated both with AF and with AF persistence, suggesting that ET-1 processing is activated during AF. Plasma brain natriuretic peptide (BNP) is a predictor of AF. In vitro, ET-1 has been reported to regulate atrial BNP expression. To assess whether this occurs in human atria, we evaluated the relationship between atrial ET-1 protein and mRNA (EDN1) with BNP mRNA (NPPB). EDN1 ( Figure 5D ) and ET-1 protein expression were both strongly correlated with NPPB expression. Atrial NPPB abundance was also associated with AF and HF (data not shown).
In addition to promoting myocyte hypertrophy, ET-1 can stimulate fibroblast proliferation and extracellular matrix deposition. Interstitial fibrosis (primarily composed of collagen) can be a critical element of the substrate for AF. We assessed the relationships between atrial ET-1 and collagen expression. The mRNA levels of collagen isoform 1 ( Figure  6A) Figure 6B ), suggesting a functional relationship between atrial ET-1 protein and development of atrial fibrosis.
Platelet derived growth factor (PDGF) signaling is implicated as a modulator of fibroblast proliferation. Connective tissue growth factor (CTGF) also promotes cardiac fibrosis, and is modulated by ET-1. Our microarray analysis suggests a coordinate regulation of both PDGF and CTGF expression by ET-1 ( Figure 6C and D) .
Discussion
In the present study, we evaluated the hypothesis that atrial ET-1 is increased in AF and is associated with LA enlargement, atrial fibrosis and AF persistence in patients with structural heart disease.
Consistent with earlier plasma studies, 14 we also found that LAA ET-1 protein levels were elevated in AF patients with HTN, HF, and MR-all conditions associated with increased hemodynamic stress. Myocyte hypertrophy and altered expression of several cardiac-specific genes are adaptive responses to hemodynamic stress. In experimental studies, ET-1 has been shown to modulate intracellular Ca 2ϩ release, 20 induce cardiac myocyte hypertrophy, 10 and modulate fibroblast proliferation and extracellular matrix deposition. 8 
Local Activation of Atrial ET-1 in AF Patients With Structural Heart Disease
Plasma ET-1 levels are reported to be elevated in patients with diastolic dysfunction and elevated atrial pressures. 21 Although circulating levels of ET-1 were reported to be elevated in AF patients with underlying cardiac disease, 14 little is known about atrial ET-1 content or its relevance to atrial pathophysiology. In a small study, pro-ET-1 mRNA and protein expression were evaluated in right atrial samples from patients with and without valvular disease, in SR or in AF. 22 Atrial ET-1 was increased with AF only in the subset with underlying valve disease. In patients with mitral valve disease, LA enlargement is profound, and LA dilatation is associated with poor clinical prognosis. 4 No studies have assessed the impact of AF or structural heart disease on LA ET-1 content or receptor expression. 
Mayyas et al Endothelin-1 and Atrial Size in AF
In the present study, we report that LA ET-1 protein is elevated in AF patients with underlying cardiac disease and that elevated ET-1 levels are associated with AF rhythm and persistence. Atrial rhythm was an important determinant of LA ET-1 content, and we documented an increased abundance of both ET-1 protein and mRNA in the fibrillating LA. This may be due to the elevated wall stress associated with AF and atrial dilatation. Although there was a trend for a reduction of LAA ETAR protein in AF patients ( Figure 5A and 5B), no significant differences in ET-1 receptor expression were detected between rhythm groups. Although modulation of ETAR by ET-1 was not strong, ETAR expression was significantly correlated with ETBR protein expression. ETAR and ETBR have opposing effects on blood pressure 9 ; the nuclear localization of ETBR may suggest a greater impact on transcriptional regulation. These data suggest a complex relationship between agonist concentration and receptor subtype distribution; ET-1 receptor expression may be regulated in an ET-1-independent manner.
The LA is frequently dilated in HF patients, even among those with preserved LV ejection fraction. 23 Development of AF in patients with MR is independently associated with HF and death. 24 HTN is also an important risk factor for AF. 1 We report that increased LAA ET-1 is associated with each of these conditions in AF patients and that this relationship is modulated by atrial rhythm. Using confocal microscopy, we show that ET-1 is present in both atrial myocytes and fibroblasts. By modulating blood pressure, LA myocyte Ca 2ϩ handling, fibroblast proliferation, cardiac hypertrophy, and the activation of cardiac specific gene programs, ET-1 may exacerbate cardiac dysfunction and accelerate the development or progression of HF and AF.
Atrial ET-1 Content and LA Geometry
Atrial structural remodeling is observed in clinical AF and in experimental AF models. 8 LA enlargement is a marker of diastolic dysfunction 25 and an independent predictor for development of postoperative AF, 3 stroke, and morbidity. 26 In a murine study, cardiac-specific overexpression of ET-1 promoted atrial and ventricular hypertrophy, dysfunction, dilatation, inflammation, and fibrosis, 27 leading to dilated cardiomyopathy and impaired survival.
LA size increases in response to both increased left ventricular filling pressure and mitral regurgitation. 24 Patients with MVD have an increased risk of developing AF. Independent risk factors for AF in MVD were age Ͼ65 years and a baseline LA size Ͼ5 cm. 24 In the present study, we demonstrate that atrial ET-1 levels are strongly correlated with both LA size and MR severity.
ET-1 and Atrial Fibrosis
The PDGF 8 and CTGF 28 signaling pathways are prominent modulators of cardiac fibrosis, and fibrosis is an important determinant of AF persistence. 32 Atrial fibroblasts are reported to be more sensitive than ventricular fibroblasts to a variety of profibrotic stimuli, including PDGF and ET-1. 8 ET-1 mRNA levels were strongly associated with expression of PDGFD and its B-type receptor mRNA (data not shown) and with CTGF. These associations probably are functionally significant because both ET1 protein and mRNA levels were associated with increased expression of the major cardiac collagen isoforms and with atrial fibrosis. In the present study, patients with permanent AF had higher atrial ET-1 levels and larger LA than those with paroxysmal AF, suggesting that AF persistence may be modulated by ET-1 production. By accelerating the development of atrial fibrosis and dilatation, ET-1 may contribute to the structural remodeling that is characteristic of persistent and permanent AF. 29 ET-1 expression is modulated at both transcriptional and posttranscriptional levels. In AF patients, both mRNA and protein levels of ET-1 were elevated. Increased ECE mRNA expression suggests that processing of atrial ET-1 may be enhanced in AF.
In recent studies, plasma levels of BNP have also been shown to predict the development of AF 30 and postoperative AF. 31 Both BNP and ET-1 expression are enhanced by hemodynamic stress. 11, 32 It is intriguing that atrial but not ventricular BNP expression is modulated by ET-1. 32 Thus, whether BNP is a marker or a mediator of AF risk is unclear. Our data show that atrial expression of BNP mRNA was strongly associated with ET-1 mRNA and protein levels. Although speculative, the prognostic value of plasma BNP as a predictor of AF 30 may depend on this relationship.
Study Limitations
A primary limitation of our study is the limited number of subjects. Ascertainment of rhythm history is challenging in surgical patients; misclassification of patients (with respect to rhythm history) would tend to minimize differences between groups. Although this study demonstrates an association of LAA ET-1 content with LA size in AF patients with underlying cardiovascular diseases, it cannot prove a causal role of ET-1 as a mediator of LA hypertrophy, dilatation, fibrosis, or AF persistence. 
Conclusions
LA dilatation is enhanced by AF in subjects with concomitant structural heart disease. Increased LAA ET-1 is associated with and may contribute to increased AF persistence and LA dilatation. Our data suggest that both ET-1 gene expression and processing are activated during AF. ET-1, in turn, enhances expression of genes involved in cardiac dilatation, hypertrophy, and fibrosis. The combined influence of these factors may contribute to the impact of ET-1 on AF persistence. Our study suggests that increased expression of atrial ET-1 is associated with the progression of atrial dysfunction. Thus, interventions that decrease atrial ET-1 expression (eg, statins, etc) or block its receptors might be useful in slowing the progression of AF.
Pharmacological strategies for treating AF are frequently directed at rhythm control and are mostly ineffective. Numerous studies have focused on the role of angiotensin II as a modulator of atrial electric and structural remodeling. In experimental studies, angiotensin receptor blockade is insufficient to prevent the development atrial fibrosis in the setting of ventricular dysfunction. ET-1 signaling may be a target for AF-focused therapeutic interventions. 
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